4Diederich S,Eigendorff E,Burkhardt P,et al.11 β-hydroxysteroid dehydrogenase types 1 and 2:an important pharmacokinetic determinant for the activity of synthetic mineralo-and glucocorticoids[J].J Clin Endocrinol Metab 2002,87 (12):5695-701.
5Ebling WF,Milsap RL,Szefler SJ,et al.6αmethylprednisolone and 6αmethylprednisolone plasma protein binding in humans and rabbits[J].J Pharm Sci 1986,75(8):760-763.
6Mollmann H,Rohdewald P,Barth J,et al.pharmacokinetics and dose linearity testing of methylprednisolone phosphate[J].Biopharm Drug Dispos,1989,10(5):453-464.
7Mollmann H,Hochhaus G,Rohatagi S,et al.pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone[J].Pharm Res 1995,12(7):1096-1100.
8shashank R,Jurgen B,Helmut M,et al.Pharmacokinetics of methylprednisolone and prednisolone after single and multi-oral administration[J].J Clin Pharmacol 1997,37:916-925.
9Kawai S,Ichikawa Y,Homma M.Differences in metabolic properties among cortisol,prednisolone,and dexamethasone in liver and renal disease:accelerated metabolism of dexamethasone in renal failure[J].J Clin Endocrinol Metab 1985,60(5):848-854.
10Milad MA,Ludwig EA,Lew KH,et al.The pharmacokinetics and pharmacodynamics of methylprednisolone in chronic re nal failure[J].Am J Ther 1994,1 (1):49-57.
